Nijagal Amar, Wegorzewska Marta, Le Tom, Tang Qizhi, Mackenzie Tippi C
Eli and Edythe Broad Center of Regeneration Medicine; UCSF; San Francisco, CA USA.
Chimerism. 2011 Apr;2(2):55-7. doi: 10.4161/chim.2.2.16287.
In utero hematopoietic cell transplantation (IUHCTx) is a promising strategy for the treatment of congenital stem cell disorders. Despite the purported immaturity of the fetal immune system, the clinical success of this strategy has been limited by poor engraftment of transplanted cells. The fetal host immune system is thought to be the major barrier to achieving successful IUHCTx. Since the fetal immune system is immature, however, we hypothesized that the maternal immune response may instead pose the true barrier to IUHCTx. We have demonstrated that maternal T cells traffic into the fetus after allogeneic in utero transplantation and that these lymphocytes play a critical role in limiting engraftment. Furthermore, we have shown that MHC matching the donor cells to the mother improves engraftment in the unmatched fetus. These results help renew interest in using the fetal environment to treat patients with congenital stem cell disorders.
宫内造血细胞移植（IUHCTx）是治疗先天性干细胞疾病的一种有前景的策略。尽管胎儿免疫系统据称不成熟，但该策略的临床成功受到移植细胞植入不佳的限制。胎儿宿主免疫系统被认为是实现成功的IUHCTx的主要障碍。然而，由于胎儿免疫系统不成熟，我们推测母体免疫反应可能反而构成IUHCTx的真正障碍。我们已经证明，同种异体宫内移植后母体T细胞会进入胎儿体内，并且这些淋巴细胞在限制植入方面起关键作用。此外，我们已经表明，将供体细胞与母亲进行主要组织相容性复合体（MHC）匹配可改善在不匹配胎儿中的植入。这些结果有助于重新激发利用胎儿环境治疗先天性干细胞疾病患者的兴趣。
